Bay Pines Foundation Inc

1. Pfizer Inc. $512,549 180 payments
2. Janssen Research & Development, LLC $210,421 64 payments
3. Kowa Research Institute, Inc. $31,241 5 payments
4. Indivior Inc. $15,925 5 payments
5. Pharmacyclics LLC, An AbbVie Company $11,750 1 payment
6. Sumitomo Pharma America, Inc. $11,135 1 payment
7. Mannkind Corporation $8,500 1 payment
8. Mirati Therapeutics, Inc. $1,000 1 payment

1. A Phase 3 Placebocontrolled Randomized Observerblinded Study to Evaluate the Efficacy Safety and Tolerability of A Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $470,680 167 payments
2. Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $61,186 33 payments
3. A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer $49,515 2 payments
4. A Phase 2a Multi Center Randomized Double blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Psoriatic Arthritis $44,675 11 payments
5. K-877-302 $31,241 5 payments
6. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer $21,374 6 payments
7. A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease $21,280 6 payments
8. A Randomized Doubleblind Placebocontrolled Study to Demonstrate the Efficacy and Longterm Safety of Pf04965842 With Topical Corticosteroids in Adult Patients With Moderatetosevere Atopic Dermatitis $18,818 8 payments
9. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $15,925 5 payments
10. An Openlabel Extension Study to Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis $12,750 2 payments

1. Non-patient care $1,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.